Novel Camel Single-Domain Antibody Specific for the Type III Mutant EGFR

سال انتشار: 1384
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 1,928

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

NBCI04_044

تاریخ نمایه سازی: 30 دی 1386

چکیده مقاله:

Camelids have a unique immune system capable of producing single-domain heavy-chain atibodies. In this study, we report the isolation and characterization of several binders against the epidermal growth factor receptor (EGFR) vIII retrieved from immune library of camels (Camelus bactrianus and Camelus dromedarius).The EGFRvIII is a ligand independent, constitutively active, mutated form of the wild-type EGFR. The expression of EGFRvIII has been demonstrated in a wide range of human malignancies, including gliomas, and breast, prostate, ovarian and lung cancer. Camels were immunized with a synthetic peptide corresponding to a mutated sequence and tissue homogenates. Single domain antibodies (VHH) were directly selected by panning a phage display library on successively decreasing amounts of synthetic peptide immobilized on magnetic beads. The anti-EGFRvIII camel single-domain antibodies selectively bound to the EGFRvIII peptide and reacted specifically with the immunoaffinity-purified antigen from a non-small cell lung cancer patient. These antibodies with affinities in the nanomolar range recognized the EGFRvIII peptide and affinity-purified mutated receptor. We concluded that using the phage display technique, antigen-specific VHH antibody fragments are readily accessible from the camelids. These antibodies may be good candidates for tumor-diagnostic and therapeutic applications.

نویسندگان

K Omidfara

Departments of aBiochemistry and bMedical Biotechnology, School of Medical Sciences, Tarbiat Modarres University

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Hemmink A: From molecular changes to customized therapy. Eur J ...
  • Gura T: Magic bullets hit the target. Nature 2002;4 17:584-586. ...
  • Hudson PJ, Souriau C: Engineering antibodies .Nat Med 2003;9: 129-134. ...
  • Funaro A, Horenstein AL, Santoro P, Cinti C, Gregorini A, ...
  • Muyldermans S: Single domain antibodies :Current status. Mol Biotechnol 2001 ...
  • Conrath KE, Wernery U, Muyldermans S, Nguyen VK: Emergence and ...
  • Lorimer IA, Keppler- Hafkemeyer A, Beers RA, Pegram CN, Bigner ...
  • Beers R, Ghowdhury P, Bigner D, Pastan I : Immun ...
  • Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, ...
  • Wikstrand CJ, Hale LP, Batra SK, Hill ML , Humphrey ...
  • Omidfar K, Rasaee MJ, Mojtahedi H, Forozandeh M, Taghikhani M, ...
  • Omidfar K, Rasaee MJ, _ Mojtahedi H, Forozandeh M, Taghikhani ...
  • نمایش کامل مراجع